Jennifer Watkins, APRN
Acute Care · Kansas City, KSNPI 1730637869
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $14,810 of the $22,583 with a category attached, or 65.6%. 34 manufacturers reported payments, led by Biohaven Pharmaceutical Holding Company Ltd. at 38.4% of the total. Reporting peaked in 2022 at $10,780 and has fallen 88.8% since, to $1,206 in 2024. Among acute care clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 535 payments — averaging $42.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceutical Holding Company Ltd.$9K
- AbbVie$8K
- Pfizer$685
- Teva Pharmaceuticals USA, Inc.$630
- Novartis$626
- CSL Behring$570
- plus $4K from 28 others
What the payments were for
- Speaking & faculty fees$14,81066%
- Travel & lodging$7363%
- Food & beverage$6,88831%
- Education$1491%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | 17 | $8,678 |
| AbbVie(2 entities) | 144 | $7,846 |
| Pfizer | 56 | $685 |
| Teva Pharmaceuticals USA, Inc. | 64 | $630 |
| Novartis | 37 | $626 |
| CSL Behring | 2 | $570 |
| Sanofi | 22 | $404 |
| Amgen | 30 | $398 |
| Bristol Myers Squibb | 33 | $362 |
| Banner Life Sciences, LLC | 18 | $312 |
| UCB, Inc. | 15 | $284 |
| EMD Serono, Inc. | 5 | $250 |
| Neurocrine Biosciences, Inc. | 8 | $170 |
| Johnson & Johnson | 11 | $155 |
| Abbott | 1 | $151 |
| Amneal Pharmaceuticals LLC | 13 | $151 |
| Biohaven Pharmaceuticals, Inc. | 13 | $120 |
| Genentech USA, Inc. | 6 | $115 |
| Lilly USA, LLC | 6 | $110 |
| SK Life Science, Inc. | 5 | $90 |
| Biogen | 4 | $80 |
| Kyowa Kirin, Inc. | 5 | $75 |
| MDD US Operations, LLC | 4 | $69 |
| Corium, LLC | 3 | $46 |
| Lundbeck LLC | 3 | $45 |
| Supernus Pharmaceuticals, Inc. | 2 | $30 |
| Avion Pharmaceuticals | 1 | $23 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Upsher-smith Laboratories LLC | 1 | $19 |
| Adamas Pharmaceuticals, Inc. | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Neurelis, Inc. | 1 | $13 |
| Impel Pharmaceuticals Inc. | 1 | $12 |
| Sumitomo Pharma America, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$8,525
- UBRELVY$6,800
- QULIPTA$5,800
- Hizentra$570
- PROCLAIM$151
How this compares
$22,583 in reported general payments places this provider in the 95th percentile of 113 acute care providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UbrelvyUbrogepant | 51 | $56,334 |
| Nurtec OdtRimegepant Sulfate | 21 | $32,932 |
| Aimovig AutoinjectorErenumab-Aooe | 30 | $29,581 |
| Emgality PenGalcanezumab-Gnlm | 16 | $11,805 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 12 | $8,567 |
| BelsomraSuvorexant | 13 | $5,684 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 96 | $1,952 |
| Levetiracetam | 70 | $1,594 |
| Memantine Hcl | 61 | $1,219 |
| Gabapentin | 79 | $1,114 |
| Duloxetine Hcl | 30 | $764 |
| Donepezil Hcl | 62 | $750 |
| Pregabalin | 20 | $637 |
| Bupropion XlBupropion Hcl | 16 | $466 |
| Primidone | 20 | $445 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy | $7,846 | $56,33451 claims |
| PfizerNurtec Odt | $685 | $32,93221 claims |
| Upsher-smith Laboratories LLCTopiramate | $19 | $10611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 113 acute care providers in Kansas.
Other acute care in Kansas City
- Kristi DuchanoisKansas City$6K
- Katie JaschkeKansas City$5K
- Abby BauerKansas City$3K
- Sara HenkelKansas City$2K
- Joseph NewmanKansas City$1K
- Jordan ShawKansas City$930
- Patrick StoffelKansas City$921
- Jean MitchellKansas City$849
- Morgan BinghamKansas City$547
- Eric AndrewKansas City$468
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.